EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer

Juan Francisco Grau Bejar iD, Elisa Yaniz Galende, Qinghe Zeng, Catherine Genestie, Etienne Rouleau, Marco de Bruyn iD, Christophe Klein, Audrey Le Formal, Elodie Edmond, Maëva Moreau, Annechien Plat, Sebastien Gouy und 6 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2024-009143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Juan Francisco Grau Bejar und 17 weiteren Autor:innen. Beteiligte Einrichtung: Gynecological Oncology Programme, Vall d'Hebron Institute of Oncology, Barcelona, Spain. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Endometrial Neoplasms, DNA Mismatch Repair. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Programme Parrainage Chercheur Institut Gustave Roussy, Comprehensive Program of Cancer Immunotherapy & Immunology I (CAIMI-I) supported by the BBVA Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) can derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and predictors of primary resistance are lacking.

Methods

We compared the immune tumor microenvironment of MMRd EC ICI-responders (Rs) and ICI non-responders (NRs), using spatial multiplexed immune profiling and unsupervised hierarchical clustering analysis.

Results

Overall, NRs exhibited drastically lower CD8 + , absent terminally differentiated T cells, lack of mature tertiary lymphoid structures and dendritic cells, as well as loss of human leukocyte antigen class I. However, no single marker could predict R versus NR with confidence. Clustering analysis identified a combination of four immune features that demonstrated that accurately predicted ICI response, with a discriminative power of 92%. Finally, 80% of NRs lacked programmed death-ligand 1, however, 60% exhibited another actionable immune checkpoint (T-cell immunoglobulin and mucin containing protein-3, indoleamine 2,3-dioxygenase 1, or lymphocyte activation gene 3).

Conclusions

These findings underscore the potential of immune tumor microenvironment features for identifying patients with MMRd EC and primary resistance to ICI who should be oriented towards trials testing novel immunotherapeutic combinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsEndometrial NeoplasmsDNA Mismatch RepairHumansFemaleTumor MicroenvironmentMiddle AgedAged

Stichwörter der Autor:innen

BiomarkerImmune Checkpoint InhibitorsTumor microenvironment - TME

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Gynecological Oncology Programme, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Gynecological Cancer Translational Research Laboratory, INSERM U981, Gustave Roussy Institute, Villejuif, France.
  • Laboratoire d'Informatique Paris Descartes (LIPADE), Université Paris Cité, Paris, France.
  • Centre d'Histologie, Imagerie cellulaire et Cytométrie (CHIC), Centre de Recherche des Cordeliers, Centre de Recherche des Cordeliers, Paris, France.
  • Pathology Department, Gustave Roussy Institute, Villejuif, France.
  • Department of Medical Biology and Pathology, Cancer Genetics Laboratory, Gustave Roussy Institute, Villejuif, France.

ORCID-Profile: Juan Francisco Grau Bejar, Marco de Bruyn, Ana Oaknin

Förderung

  • Programme Parrainage Chercheur Institut Gustave Roussy
  • Comprehensive Program of Cancer Immunotherapy & Immunology I (CAIMI-I) supported by the BBVA Foundation

Zitieren

APA

Grau Bejar, J. F., Yaniz Galende, E., Zeng, Q., Genestie, C., Rouleau, E., de Bruyn, M., Klein, C., Le Formal, A., Edmond, E., Moreau, M., Plat, A., Gouy, S., Maulard, A., Pautier, P., Michels, J., Oaknin, A., Colomba-Blameble, E., & Leary, A. (2024). Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009143

Vancouver

Grau Bejar JF, Yaniz Galende E, Zeng Q, Genestie C, Rouleau E, de Bruyn M, et al. Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009143

BibTeX
@article{GrauBejar2024,
  author = {Grau Bejar, Juan Francisco and Yaniz Galende, Elisa and Zeng, Qinghe and Genestie, Catherine and Rouleau, Etienne and de Bruyn, Marco and Klein, Christophe and Le Formal, Audrey and Edmond, Elodie and Moreau, Maëva and Plat, Annechien and Gouy, Sebastien and Maulard, Amandine and Pautier, Patricia and Michels, Judith and Oaknin, Ana and Colomba-Blameble, Emeline and Leary, Alexandra},
  title = {Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-009143}
}
Kostenlos starten →